Author:
Rise Nina,Touborg Toke,Lundsted Ditte Helene,Dalager-Pedersen Michael,Mogensen Trine H.
Abstract
Despite several reports and small case series on the disease course of SARS-CoV-2 infection in patients with inborn errors of immunity (IEI), including X-linked agammaglobulinemia (XLA), this topic remains incompletely described. Here we present the case of a 38-year-old unvaccinated man with XLA, who acquired SARS-CoV-2 infection and experienced a protracted disease course with 47 days of SARS-CoV-2 positivity, critical COVID-19 with respiratory insufficiency necessitating intensive care and ventilatory support, and prompting repeated intensified treatments with remdesivir, dexamethasone, and monoclonal antibodies to eventually control infection. We describe the disease course and treatment and review the current literature on COVID-19 susceptibility and evidence for vaccine efficacy in patients with XLA.
Subject
Immunology,Immunology and Allergy
Reference28 articles.
1. Agammaglobulinemia;Bruton;Pediatrics,1952
2. X-Linked agammaglobulinaemia: Outcomes in the modern era;Shillitoe;Clin Immunol,2017
3. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain;Mohamed;Immunol Rev,2009
4. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology;Orange;J Allergy Clin Immunol,2006
5. Clinical, immunological, and molecular analysis in a Large cohort of patients with X-linked agammaglobulinemia: An Italian multicenter study;Plebani;Clin Immunol,2002
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献